However, although the emergence of anti-HER2 drugs, trastuzumab and lapatinib, significantly improved the clinical outcome in HER2-enriched BC, the associated drug resistance problem poses challenges to effective treatment. The gene discussed is ERBB2; the disease is breast cancer.